Tag: MHRA

paclitaxel

UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for...

Following a review, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such...

UK MHRA awarded £10 million to fast-track patient access to medical...

A total of £10 million has been awarded to the Medicines and Healthcare products Regulatory Agency (MHRA)—an executive agency of the UK Department of...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the UK Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will...
reaction to meta analysis

Reaction to the Katsanos et al meta-analysis

Internal BIBA MedTech data show that perceptions on paclitaxel devices have shifted considerably in the twelve months that have elapsed since Konstantinos Katsanos (Patras,...

Highlights from the CX 2019 session, Paclitaxel: The last word

 Watch the video roundup from the CX 2019 Highlight Session, Paclitaxel: The last word. Filmed onsite at the Charing Cross Symposium (15–18 April 2019, London,...
MDA

MHRA issues medical device alert for paclitaxel use in the UK

Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
MHRA

MHRA limits routine clinical use of paclitaxel devices following expert advisory...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) acted to limit the future use of paclitaxel-eluting stents and paclitaxel-coated balloons in routine clinical...